Seliciclib

An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
051019972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Cyclins and cyclin-dependent kinases (CDK) form a key part of the regulatory proteins that govern the cell cycle. Aberrancy in… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
PURPOSE Cell cycle dysregulation resulting in expression of antiapoptotic genes and uncontrolled proliferation is a feature of… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The cell cycle governs the transition from quiescence through cell growth to proliferation. The key parts of the cell cycle… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w. Although ABT-737 triggers extensive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
The circadian timing system and the cell division cycle are frequently deregulated in cancer. The therapeutic relevance of the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
In this study, we have analyzed the consequences, on several neuroblastoma cell lines, of combined treatments with (R… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Cyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?